Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NCLH - Norwegian Cruise Drops After Offering 48 Million Shares
Norwegian Cruise is offering 47.6 million ordinary shares with another 5 million as an option for underwriter Goldman Sachs.
Shares of Norwegian Cruise Line (NCLH) - Get Report dropped Friday after the cruise operator unveiled a follow-on stock sale as it aims to resume voyages amid the coronavirus pandemic.
Norwegian shares at last check were down 16% to $37.50, its largest decline since June 2020, according to Bloomberg.
The Miami company will offer 47.6 million ordinary shares at $30 each. Goldman Sachs, the sole underwriter, gets an option to buy as many as 5 million more shares.
The offering is expected to close on March 9.
The company burned about $190 million a month in the fourth quarter as its ships remained docked due to social distancing and COVID-19 protocols. The pandemic wrecked the travel industry as people stayed home.
Last week, the company reported a wider-than-expected fourth-quarter loss.
Norwegian reported a net loss of $758.9 million, or $2.51 a share, compared with net income of $121.3 million, or 56 cents a share, in the year-earlier quarter.
The adjusted loss came to $2.33 per share, compared with the FactSet consensus for a loss of $2.17.
$CCC - Clarivate Analytics plc announces secondary offering of ordinary shares
4:40 PM ET 12/2/19 | Dow Jones
LONDON and PHILADELPHIA, Dec. 2, 2019 /CNW/ -- Clarivate Analytics Plc (NYSE:CCC; CCC.WS) (the "Company"), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, announced today that affiliated shareholders of Onex Corporation and Baring Private Equity Asia Group Ltd (BPEA), together with certain other shareholders, intend to offer an aggregate 36 million of the Company's ordinary shares in an underwritten public offering. The selling shareholders have granted the underwriters an option to purchase up to 5.4 million additional ordinary shares. The Company will not receive any of the proceeds from the sale of its ordinary shares by the selling shareholders.
Citigroup Global Markets Inc. and Goldman Sachs are acting as joint book-running managers for the offering.
The Company has filed a registration statement on Form F-1 (including a prospectus) with the Securities and Exchange Commission ("SEC") but said registration statement has not yet become effective. The ordinary shares may not be sold nor any offer to buy be accepted prior to the time the registration statement becomes effective. The filing is available for free on the Company's website (http://ir.clarivate.com) and www.sec.gov. You can also request a copy of this document by contacting Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) 831-9146 or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, email: Prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any offer of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Clarivate Analytics
Clarivate Analytics(TM) is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. We have built some of the most trusted brands across the innovation lifecycle, including Web of Science(TM), Cortellis(TM), Derwent(TM), CompuMark(TM), MarkMonitor(TM) and Techstreet(TM). Today, Clarivate Analytics is on a bold entrepreneurial mission to help customers reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.
Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics' current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics' control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise
Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.
View original content to download multimedia:http://www.prnewswire.com/news-releases/clarivate-analytics-plc-announces-secondary-offering-of-ordinary-shares-300967705.html
SOURCE Clarivate Analytics
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/02/c8341.html
/CONTACT:
Media Contact, Tabita Seagrave, Head of Communications, media.enquiries@clarivate.com; Investor Relations Contact, Anthony Gerstein, Head of Investor Relations, anthony.gerstein@clarivate.com, http://clarivate.com
Copyright CNW Group 2019
> Dow Jones Newswires
December 02, 2019 16:40 ET (21:40 GMT)
$PLUG - Plug Power Inc. Announces Proposed Public Offering of Common Stock
5:07 PM ET 12/2/19 | GlobeNewswire
Related Quotes
4:00 PM ET 12/2/19
Symbol Last % Chg
PLUG
3.80 0.00%
Real time quote.
Plug Power Inc. Announces Proposed Public Offering of Common Stock
LATHAM, N.Y., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a leader in providing clean, reliable energy solutions, today announced that it has commenced an underwritten public offering of 40 million shares of its common stock. In addition, Plug Power intends to grant the underwriters a 30-day option to purchase up to an additional 6 million shares of its common stock.
Morgan Stanley and Barclays are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Plug Power intends to use the net proceeds from the offering for working capital and other general corporate purposes, including capital expenditures.
The securities described are being offered by Plug Power pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Plug Power Inc.
The architect of modern hydrogen and fuel cell technology, Plug Power is the innovator that has taken hydrogen and fuel cell technology from concept to commercialization. Plug Power has revolutionized the material handling industry with its full-service GenKey solution, which is designed to increase productivity, lower operating costs and reduce carbon footprints in a reliable, cost-effective way. Plug Power's GenKey solution couples together all the necessary elements to power, fuel and serve a customer. With proven hydrogen and fuel cell products, Plug Power replaces lead acid batteries to power electric industrial vehicles, such as the lift trucks customers use in their distribution centers. Extending its reach into the on-road electric vehicle market, Plug Power's ProGen platform of modular fuel cell engines empowers OEMs and system integrators to rapidly adopt hydrogen fuel cell technology. ProGen engines are proven today, with thousands in service, supporting some of the most rugged operations in the world. Plug Power is the partner that customers trust to take their businesses into the future.
Plug Power Inc. Safe Harbor Statement
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (the "Company"), including, but not limited to, the risks and uncertainties related to market conditions, the expected use of proceeds, and the consummation of the proposed public offering on the terms and conditions described herein or at all. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times that, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements, including those risks and uncertainties referenced in our public filings with the SEC. For additional disclosure regarding risks and uncertainties faced by the Company, see disclosures contained in the Company's public filings with the SEC including, the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2018, and in the prospectus supplement related to the offering. You should consider these factors in evaluating the forward-looking statements included in this presentation and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update such statements as a result of new information.
Media & Investor Relations Contact:
Teal Vivacqua
Plug Power Inc.
Phone: (518) 738-0269
media@plugpower.com
> Dow Jones Newswires
December 02, 2019 17:07 ET (22:07 GMT)
$TTNP - Titan Pharmaceuticals Shares Down 52% on Public Offering TTNP
11:00 AM ET 10/16/19 | Dow Jones
By Chris Wack
Shares of Titan Pharmaceuticals Inc. (TTNP) dropped 52%, to 18 cents, after the company said a public offering priced Wednesday.
The commercial-stage therapeutics company said an underwritten public offering of 40 million units priced to the public at 22.5 cents a unit.
Titan said each unit issued in the offering consists of one share of common stock and one Class B Warrant to purchase one share of common stock.
The company said gross proceeds are expected to be $9 million.
The Class B Warrants will be immediately exercisable at a price of 22.5 a share of common stock and will expire five years from the date of issuance.
The offering is expected to close on or about Oct. 18.
Write to Chris Wack at chris.wack@wsj.com
> Dow Jones Newswires
October 16, 2019 11:00 ET (15:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering
9:20 AM ET 10/16/19 | Dow Jones
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 40,000,000 units at a price to the public of $0.225 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant in lieu thereof) and one Class B Warrant to purchase one share of common stock. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be $9.0 million.
The Class B Warrants will be immediately exercisable at a price of $0.225 per share of common stock and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants) and the accompanying warrants are immediately separable from the units and, can only be purchased together in the offering. The offering is expected to close on or about October 18, 2019, subject to customary closing conditions.
Maxim Group LLC is acting as the sole book-running manager for the offering.
Titan has granted the underwriters a 45-day option to purchase up to an additional 6,000,000 shares of common stock and/or Class B warrants to purchase up to 6,000,000 shares of common stock, at the public offering price less discounts and commissions.
The Securities and Exchange Commission (the "SEC") declared effective a registration statement on Form S-1 (File No. 333-233722) relating to these securities on October 16, 2019. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. The offering is being made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura(TM) long-term, continuous drug delivery technology. The company's lead product is Probuphine(R) (buprenorphine) implant, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACTS:
Sunil Bhonsle,
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-announces-pricing-of-9-0-million-underwritten-public-offering-300939591.html
SOURCE Titan Pharmaceuticals, Inc.
/Web site: http://www.titanpharm.com
> Dow Jones Newswires
October 16, 2019 09:20 ET (13:20 GMT)
Please keep an eye out for MEDMEN.
$LJPC - La Jolla Pharmaceutical Company Closes Offering of Common Stock
4:10 PM ET 9/15/15 | BusinessWire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the closing of its underwritten public offering of 2,932,500 shares of common stock at a public offering price of $38.00 per share, which includes the exercise of the underwriters' option to purchase up to an additional 382,500 shares of common stock. Gross offering proceeds are approximately $111.4 million, including proceeds from the exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
La Jolla intends to use the net proceeds from the offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.
Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Chardan Capital Markets, LLC, LifeSci Capital LLC and Noble Life Science Partners acted as co-managers for the offering.
The securities described above were offered pursuant to a shelf registration statement (File No. 333-197092), including a base prospectus, which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 11, 2014, and a related automatically effective registration statement filed pursuant to Rule 462(b) of the Securities Act of 1933 (File No. 333-206855). The specific terms of the offering are described in a prospectus supplement filed with the SEC in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering was made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com, or at Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (631) 274-2806, fax: (631) 254-7140.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla's novel formulation of hepcidin for the potential treatment of iron overload, which occurs as a result of diseases such as hereditary hemochromatosis (HH), beta thalassemia and sickle cell disease. LJPC-30Sa and LJPC-30Sb are La Jolla's next-generation gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150915006924r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20150915006924/en/
SOURCE: La Jolla Pharmaceutical Company
View data
La Jolla Pharmaceutical Company George F. Tidmarsh, M.D., Ph.D. President & Chief Executive Officer (858) 207-4264 gtidmarsh@ljpc.com and Dennis M. Mulroy Chief Financial Officer (858) 433-6839 dmulroy@ljpc.com
$LJPC - La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
8:00 AM ET 9/10/15 | BusinessWire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten offering of 2,550,000 shares of its common stock, offered at a price of $38.00 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 382,500 shares of common stock. The offering is expected to close on or about September 15, 2015, subject to customary closing conditions. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Chardan Capital Markets, LLC, LifeSci Capital LLC and Noble Life Science Partners are acting as co-managers for the offering.
Gross offering proceeds will be $96,900,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by La Jolla. La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-197092), including a base prospectus, which was declared effective by the United States Securities and Exchange Commission (the "SEC") on July 11, 2014, and a related automatically effective registration statement filed pursuant to Rule 462(b) of the Securities Act of 1933 (File No. 333-206855). The specific terms of the offering are described in a prospectus supplement filed with the SEC in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com, or at Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (631) 274-2806, fax: (631) 254-7140.
This press release contains statements relating to the proposed offering that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties, such as the risk that the conditions to the closing of the offering will not be satisfied. All forward-looking statements are based upon information available to La Jolla on the date the statements are first published. La Jolla undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla's novel formulation of hepcidin for the potential treatment of iron overload, which occurs as a result of diseases such as hereditary hemochromatosis (HH), beta thalassemia and sickle cell disease. LJPC-30Sa and LJPC-30Sb are La Jolla's next-generation gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150910005574r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20150910005574/en/
SOURCE: La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
858-207-4264
gtidmarsh@ljpc.com
or
Dennis M. Mulroy
Chief Financial Officer
858-433-6839
dmulroy@ljpc.com
$RDUS - Radius Health, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:30 PM ET 7/28/15 | GlobeNewswire
Radius Health, Inc. (NASDAQ:RDUS), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced the closing of its previously announced public offering of 4,662,162 shares of common stock at a public offering price of $74.00 per share, including 608,108 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares of common stock.
J.P. Morgan, BofA Merrill Lynch and Deutsche Bank Securities are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager.
The offering was made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204, or email at prospectus-eq_fi@jpmchase.com; BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, email: dg.prospectus_requests@baml.com; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, via telephone at 800-503-4611 or via e-mail: prospectus.cpdg@db.com.
CONTACT: Investor Relations
Barbara Ryan
Investor Relations
Radius Health, Inc.
203-274-2825
bryan@radiuspharm.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxNDM1MjUjMzExNDk=
$RDUS - Radius Health, Inc. Announces Pricing of Public Offering
8:03 PM ET 7/22/15 | GlobeNewswire
Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced that it has priced its public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 608,108 shares of its common stock, exercisable for 30 days.
J.P. Morgan, BofA Merrill Lynch and Deutsche Bank Securities are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A preliminary prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204, or email at prospectus-eq_fi@jpmchase.com; BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, email: dg.prospectus_requests@baml.com; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, via telephone at 800-503-4611 or via e-mail: prospectus.cpdg@db.com.
CONTACT: Investor Relations
Barbara Ryan
Investor Relations
Radius Health, Inc.
203-274-2825
bryan@radiuspharm.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxNDI4MDEjMzExNDk=
$TRXC - TransEnterix, Inc. Announces Exercise of Option to Purchase Additional Shares
7:30 AM ET 7/13/15 | BusinessWire
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced that the underwriters of its previously announced public offering of common stock partially exercised the option to purchase additional shares granted at the time of the public offering and have purchased 2,075,000 shares of common stock at the public offering price of $3.00 per share, less underwriting discounts and commissions.
Net proceeds from the original sale of 16,666,667 shares on June 17, 2015, and the partial exercise of the option to purchase additional shares on July 10, 2015, after deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $52.0 million.
As previously announced, net proceeds from this offering will be used for research and development, sales, marketing, and commercialization related to its SurgiBot(TM) System, working capital and other general corporate purposes.
Stifel and RBC Capital Markets acted as the joint book-running managers and Raymond James, BTIG and Ladenburg Thalmann acted as co-managers for the offering.
This offering was made pursuant to a prospectus supplement dated June 11, 2015 and accompanying prospectus dated December 19, 2014, filed as part of TransEnterix's effective $100 million shelf registration statement. Copies of the prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing Syndprospectus@stifel.com, or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, Attention: Equity Syndicate, by calling (877) 822-4089 or by emailing equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery by addressing the economic and clinical challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot System, a robotically enhanced laparoscopic surgical platform that allows the surgeon to be patient-side within the sterile field.
Forward Looking Statements
This press release includes statements relating to the offering of our common stock. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations and include our expectations regarding the offering and use of proceeds. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150713005412r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20150713005412/en/
SOURCE: TransEnterix
Media Contact:
TransEnterix
Mohan Nathan, 919-917-6559
mnathan@transenterix.com
or
Investor Contact:
Westwicke Partners
Mark Klausner, 443-213-0501
transenterix@westwicke.com
$AZUR - Azure Midstream Partners, LP Prices Public Offering of 3,500,000 Common Units
9:29 AM ET 6/17/15 | GlobeNewswire
Azure Midstream Partners, LP (NYSE:AZUR) (the "Partnership") today announced that it has priced its public offering of 3,500,000 common units representing limited partner interests (the "Common Units") at a price to the public of $14.17 per Common Unit. The Partnership has granted the underwriters a 30-day option to purchase up to 525,000 additional Common Units. The offering is expected to settle and close on June 22, 2015, subject to customary closing conditions. The Partnership intends to use the net proceeds from this offering, including any net proceeds from the underwriters' exercise of their option to purchase additional common units, to repay a portion of the outstanding borrowings under its revolving credit facility. Amounts repaid under our revolving credit facility may be reborrowed to fund our ongoing capital program, potential future acquisitions or for general partnership purposes.
BofA Merrill Lynch, J.P. Morgan, RBC Capital Markets and Wells Fargo Securities are acting as joint book-running managers for the offering. Baird, Stifel, Janney Montgomery Scott and Oppenheimer & Co. are acting as co-managers for the offering. The offering will be made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from:
View data
BofA Merrill Lynch J.P. Morgan 222 Broadway, New York, NY 10038 c/o Broadridge Financial Solutions Attn: Prospectus Department 1155 Long Island Avenue e-mail: dg.prospectus_requests@baml.com Edgewood, NY 11717 Telephone: (866) 803-9204 RBC Capital Markets Wells Fargo Securities Attn: Equity Syndicate Attn: Equity Syndicate Dept. 200 Vesey Street, 8th Floor 375 Park Avenue New York, NY 10281-8098 New York, NY 10152 Phone: 877-822-4089 Email: cmclientsupport@wellsfargo.com Email: equityprospectus@rbccm.com Telephone: 800-326-5897
An electronic copy of the prospectus and prospectus supplement is available from the Securities and Exchange Commission's website at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offer is being made only through the prospectus as supplemented, which is part of a shelf registration statement that became effective on April 28, 2015.
Forward Looking Statements
This press release contains forward-looking statements. These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts. In particular, statements, express or implied, concerning future actions, conditions or events, future operating results or the ability to generate revenues, income or cash flow or to make distributions are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Future actions, conditions or events and future results of operations of the Partnership may differ materially from those expressed in these forward-looking statements. Many of the factors that will determine these results are beyond the Partnership's ability to control or predict. These statements are necessarily based upon various assumptions involving judgments with respect to the future, including, among others, conditions in the capital and credit markets; the ability to achieve synergies and revenue growth; national, international, regional and local economic, competitive and regulatory conditions and developments; technological developments; inflation rates; interest rates; the political and economic stability of oil producing nations; energy markets; commodity prices; weather conditions; environmental conditions; business and regulatory or legal decisions; the timing and success of business development efforts; terrorism; and other uncertainties. In addition, an extensive list of specific material risks and uncertainties affecting the Partnership is contained in its 2014 Annual Report on Form 10-K and in our other public filings and press releases. There is no assurance that any of the actions, events or results of the forward-looking statements will occur, or if any of them do, what impact they will have on the Partnership's results of operations or financial condition. Because of these uncertainties, you are cautioned not to put undue reliance on any forward-looking statement.
About Azure Midstream Partners, LP
Azure Midstream Partners, LP, headquartered in Dallas, Texas, is a fee-based, growth oriented limited partnership formed to develop, operate, and acquire midstream energy assets. The Partnership provides natural gas gathering, transportation, and processing services; as well as NGL transportation and crude oil logistics services. The Partnership's assets include 723 miles of gathering lines in the horizontal Cotton Valley plays located in east Texas and north Louisiana and are capable of gathering 700 MMcf/d. The Partnership also has two natural gas processing facilities located in Panola County, Texas, and a natural gas processing facility located in Tyler County, Texas with 300 MMcf/d of cumulative processing capacity, two NGL transportation pipelines that connect its Panola County and Tyler County processing facilities to third party NGL pipelines capable of transporting 21,000 barrels per day, and three crude oil transloading facilities containing six crude oil transloaders with capacity to load 22,528 barrels per day.
View data
CONTACT: Institutional Investor Contact: Azure Midstream Partners, LP Eric T. Kalamaras - Chief Financial Officer (214) 206-9499 Retail Investor Contact: Azure Midstream Partners, LP Stephen Ciupak - Director of Financial Strategy (214) 646-1583 Media Relations Contact: Steven C. Sullivan (518) 587-5995
http://media.globenewswire.com/cache/27344/small/34277.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzg4NDIjMjczNDQ=
$ONVO - Organovo Holdings, Inc. Prices $40 Million Public Offering of Common Stock
8:56 AM ET 6/18/15 | PR Newswire
Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo" or the "Company") today announced the sale of 9,425,000 shares of its common stock in an underwritten public offering at a price to the public of $4.25 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,413,750 shares of common stock on the same terms and conditions. The gross offering proceeds to Organovo from the sale of the shares are expected to be $40,056,250, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding any proceeds from the exercise of the underwriters' option. The offering is expected to close on or about June 23, 2015, subject to customary closing conditions.
The Company anticipates using the net proceeds from this offering for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as a co-manager for the offering.
The shares described above will be offered pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). Organovo intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained by sending a request to: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, New York 10022, by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-503-4611, or by e-mailing prospectus@pjc.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Organovo, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo believes these 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on the Company's current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the ability to complete the proposed offering; risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its annual report on Form 10-K filed with the SEC on June 9, 2015, its preliminary prospectus supplement filed with the SEC on June 17, 2015, its final prospectus supplement to be filed with the SEC and its other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Barry Michaels, Chief Financial Officer, (858) 224-1000 ext. 3, IR@organovo.com
Gerry Amato, Amato and Partners, LLC, Investor Relations Counsel, admin@amatoandpartners.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-prices-40-million-public-offering-of-common-stock-300101334.html
SOURCE Organovo Holdings, Inc.
$TRXC - TransEnterix prices equity offering
Jun 12 2015, 07:22 ET | By: Douglas W. House, SA News Editor
TransEnterix (NYSEMKT:TRXC) prices its public offering of 16,666,667 shares of common stock at $3 per share. Underwriters over-allotment is an additional 2.5M shares.
Closing date is June 17. Net proceeds will fund R&D, the commercialization of the SurgiBot System, working capital and general corporate purposes.
Yesterday's close was $3.14.
$TRXC - Transenterix announces a proposed public offering of common stock; offering size and price not disclosed
7:02 AM ET 6/8/15 | Briefing.com
Co plans to use the net proceeds from this offering for research and development, sales, marketing, and commercialization related to its SurgiBot System, working capital and other general corporate purposes.
$FTR - Frontier Communications prices offerings of $750 mln of common stock and $1.750 bln of Mandatory Convertible Preferred Stock
2:08 AM ET 6/5/15 | Briefing.com
Co priced its previously announced registered offerings of $750 million of common stock, at a public offering price of $5.00 per share, and $1.750 billion of 11.125% Mandatory Convertible Preferred Stock, Series A, at a public offering price of $100.00 per share.
$CVRS - Corindus Vascular Robotics Announces Proposed Public Offering of Common Stock
Corindus Vascular Robotics, Inc. (OTCQB:CVRS), a leading developer of precision vascular robotics, today announced that it plans to offer 11,000,000 shares of its common stock in an underwritten public offering. Corindus Vascular Robotics also expects to grant the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Corindus Vascular Robotics. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Cowen and Company and Stifel are acting as joint book-running managers for the offering. National Securities Corporation is acting as co-manager for the offering.
Corindus Vascular Robotics has filed a registration statement on Form S-1, including a preliminary prospectus, with the Securities and Exchange Commission, or SEC, relating to the public offering of the shares of common stock described above. A copy of the preliminary prospectus relating to these securities may be obtained, when available, by contacting Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by calling (631) 274-2806 or by faxing (631) 254-7140, or Stifel, Nicolaus & Company, Incorporated, Attn: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by calling (415) 364-2720 or by emailing syndprospectus@stifel.com. An electronic copy of the preliminary prospectus relating to the offering is also available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
http://www.sys-con.com/node/3338489
$BOJA - Bojangles' Soars in Market Debut
May 08, 2015 13:58:00 (ET)
By Lisa Beilfuss
Shares of Bojangles' Inc. soared as much as 47% in their market debut Friday as investors piled into the North Carolina-based chicken chain.
The stock opened at $26.55, 40% above its initial public offering price of $19, and quickly ran to a high of $27.97 before retreating. The shares, listed on the Nasdaq under the symbol "BOJA," recently traded at $25.10 in afternoon trading.
The current stock price values the company at about $900 million.
Earlier this week, the company upped the terms of the offering and said it expected shares to price between $18 and $19 a share.
In an interview, Chief Executive Clifton Rutledge said, "It's been a great day for our brand and a great day for our employees and franchisees."
Bojangles' hopes to build on Americans' growing appetite for breakfast on the go, and it is entering the market as KFC, the chicken chain owned by Yum Brands Inc., last quarter reported its strongest U.S. same-store sales growth in a decade.
The restaurant operator sells a variety of southern fare, including breakfast biscuits and fried chicken dinners, in addition to salads and wraps. Breakfast represents about 38% of sales.
Over the next five to seven years, Mr. Rutledge said the company could "double its footprint" while taking a disciplined approach to store growth.
The CEO projects store growth between 7%-8%, a rate that is in line with its store expansion over the past several years.
"We won't jump states--it's not about putting dots on a map," the CEO said. For now, Bojangles' plans to concentrate growth in North Carolina and adjacent states, but it could eventually open shops outside of the region.
Founded in 1977, Bojangles' counted 258 company-operated and 377 franchised restaurants at the end of March. In 2014, the company generated $430.5 million in revenue, up 15% from a year earlier.
The offering was led by Bank of America Corp, Wells Fargo & Co. and Jefferies.
Restaurant stocks traditionally have performed well in market debuts. In the past 10 years, the average one-day pop for restaurant stocks topped 40%, according to Dealogic.
Shares of Shake Shack Inc. and Habit Restaurants Inc., the last two restaurants to go public, more than doubled in their stock-market debuts. The restaurant IPO before those burger chains, and what many investors view as Bojangles' closest peer, was El Pollo Loco Holdings Inc. Its stock jumped 60% in its first day of trading.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
Access Investor Kit for Bank of America Corp.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US0605051046
Access Investor Kit for Wells Fargo & Co.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US9497461015
Access Investor Kit for Yum! Brands, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US9884981013
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
May 08, 2015 13:58 ET (17:58 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
$ALQA - Alliqua BioMedical, Inc. Announces Closing of $34.5 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
4:05 PM ET 5/4/15 | GlobeNewswire
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced the closing of its previously announced underwritten offering of 6,593,407 shares of its common stock at a public offering price of $4.55 per share. In addition, the underwriters have exercised their over-allotment option in full to purchase an additional 989,011 shares of common stock at the public offering price.
All of the shares in the offering were sold by Alliqua, with total gross proceeds to the Company of $34.5 million, before deducting underwriting discounts and estimated offering expenses.
Cowen and Company, LLC and RBC Capital Markets, LLC acted as the joint book-running managers for the offering, and Craig-Hallum Capital Group LLC acted as co-manager.
The Company intends to use the net proceeds from this offering to fund the commercial expansion of its marketed products, to opportunistically pursue additional product platforms, and for working capital and general corporate purposes.
The public offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective on September 25, 2014. A final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC on April 29, 2015 and is available on the SEC's website located at http://www.sec.gov, and copies may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806; or from RBC Capital Markets, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, or by phone at (877) 822-4089 or by emailing equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal(R) and Hydress(R) brands, as well as the sorbion sachet S(R) and sorbion sana(R) wound care products, and its TheraBond 3D(R) advanced dressing which incorporates the TheraBond 3D(R) Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance(R), as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. Such statements are based on management's good faith expectations and are subject to numerous factors, risks and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, failure to consummate or delay in consummating the Celleration acquisition; the adequacy of the Company's liquidity to pursue its complete business objectives; inadequate capital; the Company's ability to obtain reimbursement from third-party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on February 24, 2015, our most recent Form 10-Q filings with the SEC and the final prospectus supplement filed with the SEC on April 29, 2015 in connection with the public offering. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. After the date of this press release, we do not intend to update any of the forward-looking statements to conform those statements to actual results or to changes in the Company's expectations, except as required by law.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
http://media.globenewswire.com/cache/30246/small/24920.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzIzOTUjMzAyNDY=
Alliqua BioMedical, Inc. Announces Pricing of Public Offering of Common Stock
8:40 AM ET 4/29/15 | GlobeNewswire
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced the pricing of an underwritten public offering of 6,593,407 shares of its common stock at a price to the public of $4.55 per share. The offering is expected to close on or about May 4, 2015, subject to customary closing conditions. Alliqua has granted the underwriters a 30-day option to purchase up to 989,011 additional shares of common stock to cover overallotments, if any.
Cowen and Company, LLC and RBC Capital Markets, LLC are acting as the joint book-running managers for the offering, and Craig-Hallum Capital Group LLC is acting as co-manager.
The Company intends to use the net proceeds from this offering to fund the commercial expansion of its marketed products, to pursue additional product platforms, and for working capital and general corporate purposes.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on September 25, 2014. A preliminary prospectus supplement relating to the offering was filed with the SEC on April 28, 2015 and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806; or from RBC Capital Markets, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, or by phone at (877) 822-4089 or by emailing equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal(R) and Hydress(R) brands, as well as the Sorbion sachet S(R) and Sorbion sana(R) wound care products, and its TheraBond 3D(R) advanced dressing which incorporates the TheraBond 3D(R) Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance(R), as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. Such statements are based on management's good faith expectations and are subject to numerous factors, risks and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, failure to consummate or delay in consummating the Celleration acquisition; the adequacy of the Company's liquidity to pursue its complete business objectives; inadequate capital; the Company's ability to obtain reimbursement from third-party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on February 24, 2015, our most recent Form 10-Q filings with the SEC and the preliminary prospectus filed with the SEC on April 28, 2015 in connection with the public offering. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. After the date of this press release, we do not intend to update any of the forward-looking statements to conform those statements to actual results or to changes in the Company's expectations, except as required by law.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
http://media.globenewswire.com/cache/30246/small/24920.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzE0MjYjMzAyNDY=
$INO - Inovio Pharmaceuticals Announces Public Offering of Common Stock
4:01 PM ET 4/29/15 | GlobeNewswire
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) ("Inovio" or the "Company"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission on August 8, 2014. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at prospectus@pjc.com; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720 or email at syndprospectus@stifel.com.
This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Inovio being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995 relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including that the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, and uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon(R) active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
http://media.globenewswire.com/cache/34383/small/31572.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzE1ODQjMzQzODM=
$NVGN - Novogen Conducts Private Placement and Announces Rights Offering to Shareholders
7:00 AM ET 4/21/15 | PR Newswire
Novogen Limited (ASX:NRT; NASDAQ:NVGN) ("Company" or "Novogen"), an Australian/US biotechnology company, advises that it has entered into definitive agreements today to issue approximately 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of approximately AU$15,500,000 ("Placement"). The closing of the Placement is expected to occur on or about 24 April 2015 and is subject to satisfaction of customary closing conditions. The issue of the attaching options under the Placement is subject to shareholder approval.
HC Wainwright & Co. is the exclusive placement agent for the Placement.
To provide an opportunity for existing shareholders of the Company to participate at the same price, the Company will be undertaking a 1 for 6 non-renounceable rights issue offering of fully-paid ordinary shares to raise up to a maximum of approximately A$15,000,000 ("Rights Issue"). Participants will also receive, for no additional cash consideration, one 6-month option and half of one 5-year option for every one share issued under the Rights Issue. The Rights Issue will be open to eligible shareholders who hold shares as at 5.00pm (AEST) on Friday 1 May 2015 ("Record Date"). The Rights Issue is expected to close at 5.00pm (AEST) on 29 May 2015. Eligible shareholders will be invited to apply for additional shares together with attaching options in excess of their entitlement. The directors have reserved the right to place any shortfall within 3 months of close of the Rights Issue.
Lodge Partners Pty Ltd (http://www.lodgepartners.com.au/) and HC Wainwright & Co. will co-manage the placement of any shortfall in the Rights Issue.
Under the terms of the Placement and the Rights Issue, the Company proposes to raise up to AU$30,500,000 through the issue of an aggregate of up to approximately 98.7 million fully-paid ordinary shares at a price of AU$0.30 each, comprising approximately 51 million shares under the Placement and up to approximately 47 million shares under the Rights Issue.
The AU$0.30 issue price represents a 10% discount to the 5-day VWAP leading up to Friday 17 April 2015.
The Company has also in aggregate agreed to grant to the investors under both the Placement and the Rights Issue, for no additional cash consideration:
-- 6-month options to purchase up to an aggregate of approximately 98 million ordinary shares at an exercise price of A$0.30 per option; and
-- 5-year options to purchase up to an aggregate of approximately 49 million ordinary shares at an exercise price of A$0.40 per option.
Issuance of the options under the Placement is subject to Novogen receiving shareholder approval at a general meeting, which is expected to be held in June 2015. The issuance of the options under the Rights Issue will not require shareholder approval. The exercise price of the options will be subject to future adjustment for various events required under ASX Listing Rules, such as stock splits.
The securities offered and sold in the Placement have not been registered under the Securities Act of 1933, as amended, or any United States state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Company has agreed to cause the registration in the United States of ADRs representing the ordinary shares purchased by the United States investors and the shares underlying the options for resale in the United States.
The Company intends to use the proceeds of the Placement and the Rights Issue for ongoing and future research programs into the development of the Company's drug pipeline and for working capital purposes.
Notices containing further details in relation to the Rights Issue, including the proposed timetable, will be sent to shareholders and optionholders of Novogen shortly. A copy of those notices will also be made available on the ASX website at asx.com.au under the code "NRT" and the Company's website at www.novogen.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction.
Graham Kelly, Novogen Group CEO, said, "The Company is about to enter a significant growth phase. The last two years have been about laying the groundwork with our two technology platforms. That work has brought us now to a position of being in a position to exploit the considerable opportunities that those two proprietary drug technology platforms offer.
"We have identified 3 needs for funding. The first is to provide a runway for our 3 lead oncology candidate drugs to put them in a position (Phase 1b/2a, Phase 0) where we might expect to see objective evidence of clinical benefit.
"The second need is to build on the highly promising data we are seeing with both technology platforms in a range of non-oncology fields. Five such programs are underway, each with the potential to develop into major new areas of therapeutic opportunity.
"The third need is to retain our independence in order to maximize shareholder value. Novogen has the opportunity to grow quickly into a significant drug discovery company. The further we take that opportunity as an independent company, the greater the shareholder value. I believe that the Company has the intellectual property and the management expertise to achieve its goal of becoming a major player in the international biotechnology sector, and the fund-raising that we have announced today is key to that," Kelly added.
About Novogen Limited
Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell.
The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.
The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina).
Further information is available on our website www.novogen.com.
For more information please contact:
View data
Corporate Contact Media Enquiries Dr. Graham Kelly Cristyn Humphreys Executive Chairman & CEO Chief Operating Officer Novogen Group Novogen Group Graham.Kelly@novogen.com Cristyn.Humphreys@novogen.com +61 (0) 2 9472 4100 +61 (0) 2 9472 4111
Forward Looking Statement
All statements other than statements of historical fact included in this announcement including, without limitation, statements regarding future plans and objectives of Novogen Limited ("Novogen") are forward-looking statements. When used in this announcement, forward-looking statements can be identified by words such as 'may', 'could', 'should', 'would', 'believes', 'estimates', 'targets', 'expects' or 'intends' and other similar words that involve risks and uncertainties.
Such statements relate to future events and expectations and as such involve known and unknown risks and uncertainties. These risks and uncertainties include, among other things, market conditions, weather risks, economic and political risks.
These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this announcement, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Novogen, its directors and management, which could cause Novogen's actual results to differ materially from the results expressed or anticipated in these statements.
Novogen cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements. Actual results, actions, and developments may differ materially from those expressed or implied by those forward-looking statements depending on a variety of factors.
Novogen does not undertake to update or revise forward- looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, except where required by applicable law and stock exchange listing requirements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novogen-conducts-private-placement-and-announces-rights-offering-to-shareholders-300069147.html
SOURCE Novogen Ltd
Thought this was a interesting source.
http://www.marketwatch.com/investing/crowdnetic?page=dashboard
$LGF - Lionsgate Announces Pricing of Secondary Offering by Funds Affiliated with MHR Fund Management
9:00 AM ET 4/8/15 | PR Newswire
Lionsgate (NYSE: LGF) (the "Company" or "Lionsgate") announced today the pricing of an underwritten secondary offering of 10,000,000 shares of its common shares offered by investment funds affiliated with MHR Fund Management LLC at a public offering price of $32.00 per share. These investment funds have granted to the underwriter a 30-day option to purchase up to an additional 1,500,000 common shares. Lionsgate will not sell any shares in the offering and will not receive any proceeds from the offering. The offering is expected to close on or about April 13, 2015, subject to customary closing conditions.
http://photos.prnewswire.com/prnvar/20130919/LA83194LOGO
J.P. Morgan Securities LLC is acting as sole underwriter for the offering.
The common shares are being offered and sold pursuant to an effective registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3 and available for review on the SEC's website at www.sec.gov.
When available, copies of the prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling 1 (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
For further information, please contact:Peter WilkesLionsgate310-255-3726pwilkes@lionsgate.com
or
Cristina CastanedaLionsgate310-255-5114ccastaneda@lionsgate.com
The matters discussed in this press release may constitute forward-looking statements. Such statements are subject to a number of risks and uncertainties. Actual results in the future could differ materially and adversely from those described in the forward-looking statements as a result of various important factors, including the substantial investment of capital required to produce and market films and television series, increased costs for producing and marketing feature films and television series, budget overruns, limitations imposed by our credit facility and notes, unpredictability of the commercial success of our motion pictures and television programming, the cost of defending our intellectual property, difficulties in integrating acquired businesses, risks related to our acquisition strategy and integration of acquired businesses, the effects of disposition of businesses or assets, technological changes and other trends affecting the entertainment industry, and the risk factors as set forth in Lionsgate's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on May 29, 2014 and its most recent Quarterly Report on Form 10-Q, filed with the SEC on February 5, 2015. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.
Logo - http://photos.prnewswire.com/prnh/20130919/LA83194LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lionsgate-announces-pricing-of-secondary-offering-by-funds-affiliated-with-mhr-fund-management-300062722.html
SOURCE Lionsgate
$ICPT - Intercept Pharmaceuticals Announces Proposed Offering of Common Stock
6:24 AM ET 3/31/15 | GlobeNewswire
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced that it is commencing an underwritten public offering of 1,200,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept. The underwriters intend to offer the shares of common stock from time to time for sale in one or more transactions on The Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Intercept intends to grant the underwriters a 30-day option to purchase up to an additional 180,000 shares of common stock, on the same terms and conditions.
Intercept intends to use the net proceeds of this offering to support the expansion of its clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, the clinical development program for obeticholic acid (OCA) in primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), the expansion of OCA manufacturing activities, advancement of INT-767 and other preclinical pipeline programs, and the preparation for and potential initiation of the commercial launch of OCA in PBC in the United States and certain European countries in 2016. The balance, if any, will be used for general corporate purposes.
UBS Investment Bank and Citigroup are acting as underwriters in the offering.
A preliminary prospectus supplement relating to the offering has been filed with the Securities and Exchange Commission (the SEC). Copies of the preliminary prospectus supplement may be obtained from the offices of UBS Investment Bank c/o Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by calling 1-888-827-7275; or Citigroup c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at prospectus@citi.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
The securities described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 previously filed by Intercept with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases. The company's lead product candidate, obeticholic acid (OCA), is a first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases, including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. The FDA has granted OCA breakthrough therapy designation for the treatment of NASH with fibrosis and granted OCA fast track designation for the treatment of patients with PBC who have an inadequate response to or are intolerant of ursodiol. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. Additional information about Intercept is available in the company's public filings, which are available at the SEC's EDGAR database available online at www.sec.gov.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated final terms, timing and completion of the offering; the use of proceeds of the offering; clinical and regulatory developments for OCA, the anticipated timeframe for the commencement, completion and receipt of results from the clinical trials in OCA and for the making of regulatory submissions; the anticipated results of the company's clinical and preclinical trials and other development activities; and Intercept's strategic directives under the caption "About Intercept." Intercept may not be able to complete the offering of common stock on the anticipated terms, or at all. The "forward-looking statements" in this press release are based on management's current expectations of future events and are subject to a number of important risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: whether or not the company will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering, the impact of general economic, industry or political conditions in the United States or internationally; the initiation, cost, timing, progress and results of Intercept's development activities, preclinical studies and clinical trials; the timing of and Intercept's ability to obtain and maintain regulatory approval of OCA, INT-767 and any other product candidates it may develop, particularly the possibility that regulatory authorities may require clinical outcomes data (and not just results based on achievement of a surrogate endpoint) as a condition to any marketing approval for OCA, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; Intercept's plans to research, develop and commercialize its product candidates; the election by Intercept's collaborators to pursue research, development and commercialization activities; Intercept's ability to attract collaborators with development, regulatory and commercialization expertise; Intercept's ability to obtain and maintain intellectual property protection for its product candidates; Intercept's ability to successfully commercialize its product candidates; the size and growth of the markets for Intercept's product candidates and its ability to serve those markets; the rate and degree of market acceptance of any future products; undesirable side effects that may be found in Intercept's product candidates that may delay or prevent regulatory approval or require the company's product candidates to include safety warnings or be taken off the market; the success of competing drugs that are or become available; regulatory developments in the United States and other countries; the performance of third-party suppliers and manufacturers; Intercept's need for and ability to obtain additional financing; Intercept's estimates regarding expenses, future revenues and capital requirements and the accuracy thereof; Intercept's ability to retain key scientific or management personnel; and other factors discussed under the heading "Risk Factors" contained in Intercept's annual report on Form 10-K for the year ended December 31, 2014 filed on March 2, 2015 and in the preliminary prospectus supplement related to the proposed offering filed with the SEC on the date of this press release. All information in this press release is as of the date of the release, and Intercept undertakes no duty to update this information unless required by law.
CONTACT: For more information about Intercept,
please contact Barbara Duncan or Senthil Sundaram,
both of Intercept Pharmaceuticals at +1-646-747-1000.
Media inquiries: media@interceptpharma.com
Investor inquiries: investors@interceptpharma.com
http://media.globenewswire.com/cache/23024/small/25215.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMjY5NzMjMjMwMjQ=
$TKMR - Tekmira Announces Completion of Underwritten Public Offering of Common Shares
Mar 25, 2015 11:24:00 (ET)
Tekmira Announces Completion of Underwritten Public Offering of Common Shares
VANCOUVER, British Columbia, March 25, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has completed its previously announced underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses. Tekmira also granted the underwriters a 30-day option to purchase up to an additional 1.125 million common shares, which, if exercised, would result in additional gross proceeds of US$22.8 million.
Tekmira anticipates using the net proceeds from this offering to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.
Leerink Partners LLC and RBC Capital Markets, LLC acted as the lead book-runners for the offering. Nomura acted as a book-runner for the offering. Co-managers for the offering were: JMP Securities, Wedbush PacGrow and Lazard Frères & Co.
The offering was made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. No securities were offered, sold or delivered, directly or indirectly, in Canada or to any resident of Canada. A prospectus supplement relating to the offering was filed with the SEC. Copies of the prospectus supplement relating to these securities may also be obtained from: Leerink Partners LLC; Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or via telephone at (800) 808-7525, or by email at syndicate@leerink.com; or from RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; phone: (877) 822-4089; email: equityprospectus@rbccm.com.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV). Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. Our portfolio of assets includes eight drug candidates for use in combination to develop a cure for HBV, and includes our product TKM-HBV currently in Phase 1 clinical studies.
We also have a pipeline of non-HBV assets in oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle(LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body's own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. We intend to maximize the value of our non-HBV assets in the clinic, namely: TKM-PLK1 for advanced gastrointestinal neuroendocrine tumors, adrenocortical carcinoma and hepatocellular carcinoma; and TKM-Ebola, and TKM-Ebola-Guinea for ebola virus disease; as well as our preclinical programs in metabolic disorders and filoviruses.
Tekmira is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.tekmira.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about a 30-day option to purchase additional common shares; additional gross proceeds; anticipated use of net proceeds; Tekmira's strategy to develop a curative regimen for HBV; the potential of RNAi and LNP technology; and Tekmira's intent to maximize the value of their non-HBV assets.
With respect to the forward-looking statements contained in this press release, Tekmira has made numerous assumptions regarding, among other things: stability of economic and market conditions; and the continued demand for Tekmira's assets. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: Tekmira's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira's research and development capabilities and resources will not meet current or expected demand; Tekmira's products may not prove to be effective in the treatment of cancer and infectious diseases; the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; the FDA will not approve the commencement of Tekmira's planned clinical trials or approve the use of Tekmira's products and generally, difficulties or delays in the progress, timing and results of clinical trials; the FDA may determine that the design and planned analysis of Tekmira's clinical trials do not adequately address the trial objectives in support of Tekmira's regulatory submissions; pre-clinical and clinical trials may be more costly or take longer to complete than anticipated; pre-clinical or clinical trials may not generate results that warrant future development of the tested drug candidate; and the possibility that Tekmira has not sufficiently budgeted for expenditures necessary to carry out planned activities.
A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Report on Form 10-K and Tekmira's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
CONTACT: Investors
Julie P. Rezler
Director, Investor Relations
Phone: 604-419-3200
Email: jrezler@tekmira.com
Media
Please direct all media inquiries to media@tekmira.com
(MORE TO FOLLOW) Dow Jones Newswires
March 25, 2015 11:24 ET (15:24 GMT)
Correction to Whiting Petroleum Article on March 23
1:09 PM ET 3/25/15 | Dow Jones
"Whiting Petroleum Gives Signal Deal May Not Be Imminent" at 6:50 p.m. EDT on March 23 incorrectly characterized the company's debt offering as being just in convertible senior notes. Instead, Whiting is offering $1 billion in convertible senior notes due 2020 and $750 million in senior notes due 2023.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Took a starter in TKMR @ $17.63
$MBLY - Mobileye Announces Closing of Secondary Public Offering
9:40 AM ET 3/20/15 | PR Newswire
Mobileye N.V. (NYSE: MBLY), the global leader in the design and development of camera-based Advanced Driver Assistance Systems, announced today that it closed the offering of 19,696,050 ordinary shares by selling shareholders in a registered public offering at $41.75 per share. The shares sold included 2,569,050 ordinary shares that the underwriters acquired pursuant to exercise of their option to purchase additional ordinary shares. The Company did not receive any proceeds from the offering.
http://photos.prnewswire.com/prnvar/20140721/128803
Goldman, Sachs & Co. and Morgan Stanley & Co. LLC acted as lead book-running managers for the offering. Deutsche Bank Securities Inc. was a joint book-running manager and Barclays Capital Inc. and Citigroup also acted as book-running managers. Raymond James & Associates, Inc., William Blair & Company, L.L.C. and Wells Fargo Securities, LLC acted as co-managers.
The offering was made only by means of a prospectus. A copy of the prospectus for the offering may be obtained by contacting Goldman, Sachs & Co., Attn.: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526, or email: prospectus-ny@ny.email.gs.com; or Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn.: Prospectus Department, or by calling (866) 718-1649, or by emailing prospectus@morganstanley.com.
A registration statement relating to these securities was filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.
About Mobileye N.V.
Mobileye N.V. is the global leader in the design and development of software and related technologies for camera-based Advanced Driver Assistance Systems. Our technology keeps passengers safer on the roads, reduces the risks of traffic accidents, saves lives and has the potential to revolutionize the driving experience by enabling autonomous driving. Our proprietary software algorithms and EyeQ(R) chips perform detailed interpretations of the visual field in order to anticipate possible collisions with other vehicles, pedestrians, cyclists, animals, debris and other obstacles. Mobileye's products are also able to detect roadway markings such as lanes, road boundaries, barriers and similar items, as well as to identify and read traffic signs and traffic lights. Our products are integrated into car models from 23 global automakers including BMW, Ford, General Motors, Nissan and Volvo. Our products are also available in the aftermarket.
Forward-Looking Statements
This press release may contain certain forward-looking statements, including statements with regard to the securities offering. Words such as "believes," "intends," "expects," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, and are subject to numerous factors, many of which are beyond the control of Mobileye, including, without limitation, the risk factors and other matters set forth in the registration statement for the offering filed with the U.S. Securities and Exchange Commission. Mobileye undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
CONTACT: Yonah Lloyd
Chief Communications Officer / SVP Business Development
+972-2-541-7367
yonah.lloyd@mobileye.com
Logo - http://photos.prnewswire.com/prnh/20140721/128803
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mobileye-announces-closing-of-secondary-public-offering-300053640.html
SOURCE Mobileye N.V.
$TKMR - Tekmira Announces Pricing of Underwritten Public Offering of Common Shares
9:00 AM ET 3/20/15 | GlobeNewswire
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has priced an underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses.
Tekmira has also granted the underwriters a 30-day option to purchase up to an additional 1.125 million common shares, which, if exercised, would result in additional gross proceeds of US$22.8 million. The offering is expected to close on or about March 25, 2015, subject to the satisfaction of customary closing conditions.
Tekmira anticipates using the net proceeds from this offering to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.
Leerink Partners LLC and RBC Capital Markets, LLC are acting as the lead book-runners for the offering. Nomura is acting as a book-runner for the offering. Co-managers for the offering are: JMP Securities, Wedbush PacGrow and Lazard Freres & Co.
The offering is being made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. No securities are being offered, sold or delivered, directly or indirectly, in Canada or to any resident of Canada. A prospectus supplement relating to the offering is being filed with the SEC. Copies of the prospectus supplement relating to these securities may also be obtained from: Leerink Partners LLC; Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or via telephone at (800) 808-7525, or by email at syndicate@leerink.com; or from RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; phone: (877) 822-4089; email: equityprospectus@rbccm.com.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV). Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. Our portfolio of assets includes eight drug candidates for use in combination to develop a cure for HBV, and includes our product TKM-HBV currently in Phase 1 clinical studies.
We also have a pipeline of non-HBV assets in oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle (LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body's own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. We intend to maximize the value of our non-HBV assets in the clinic, namely: TKM-PLK1 for advanced gastrointestinal neuroendocrine tumors, adrenocortical carcinoma and hepatocellular carcinoma; and TKM-Ebola, and TKM-Ebola-Guinea for ebola virus disease; as well as our preclinical programs in metabolic disorders and filoviruses.
Tekmira is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.tekmira.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about the pricing of common shares in an underwritten public offering; aggregate gross proceeds; deductions of underwriting discounts and other estimated offering expenses; a 30-day option to purchase additional common shares; additional gross proceeds; anticipated closing date; satisfaction of customary conditions; use of net proceeds; the filing and delivery of a prospectus; Tekmira's strategy to develop a curative regimen for HBV; the potential of RNAi and LNP technology; and Tekmira's intent to maximize the value of their non-HBV assets.
With respect to the forward-looking statements contained in this press release, Tekmira has made numerous assumptions regarding, among other things: regulatory approval of the financing; the ability of the parties to satisfy the required conditions of closing; stability of economic and market conditions; and the continued demand for Tekmira's assets. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the proposed underwritten offering of common shares may not be completed on the terms and in the timeframe currently anticipated, or at all; a prospectus for the proposed underwritten offering may not be filed or delivered in the timeframe contemplated, or at all; the parties may not be able to satisfy the required conditions of closing, and thus be unable to complete the transaction; Tekmira's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira's research and development capabilities and resources will not meet current or expected demand; Tekmira's products may not prove to be effective in the treatment of cancer and infectious diseases; the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; the FDA will not approve the commencement of Tekmira's planned clinical trials or approve the use of Tekmira's products and generally, difficulties or delays in the progress, timing and results of clinical trials; the FDA may determine that the design and planned analysis of Tekmira's clinical trials do not adequately address the trial objectives in support of Tekmira's regulatory submissions; pre-clinical and clinical trials may be more costly or take longer to complete than anticipated; pre-clinical or clinical trials may not generate results that warrant future development of the tested drug candidate; and the possibility that Tekmira has not sufficiently budgeted for expenditures necessary to carry out planned activities.
A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Report on Form 10-K and Tekmira's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
CONTACT: Investors
Julie P. Rezler
Director, Investor Relations
Phone: 604-419-3200
Email: jrezler@tekmira.com
Media
Please direct all media inquiries to media@tekmira.com
http://media.globenewswire.com/cache/14025/small/25130.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMjU3MzQjMTQwMjU=
welcome to the board SK! Enjoy the weekend
OXiGENE raises $10M in direct offering
Mar 20 2015, 08:54 ET | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip
In a direct offering to institutional investors, OXiGENE (NASDAQ:OXGN) sells $10M of common stock at $1.7125 per share plus a warrant to purchase one half share of common stock at $1.7125 for a five-year term. Closing date is March 25.Net proceeds will fund the advancement of fosbretabulin, OXi4503 and general corporate purposes.
http://seekingalpha.com/news/2382306-oxigene-raises-10m-in-direct-offering
Hi SK, glad ya stopped by.....welcome.....
Good Morning, thought I'd stop by and see what you guys were up to. This is a great idea by the way. Much $ to be made playing these type of plays if you know what you're doing.
Very nice Buddy, I was asleep at the wheel on that one......I still think you are onto something with this board. I'd have to spend a few hrs going over multiple stocks having done PO's, go over their charts and be ready for future plays and when they are ready to pop.....Good job, hope you had it......or have.....
$GALE - nice bounce off the PO
$GALE - Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
4:01 PM ET 3/12/15 | GlobeNewswire
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced it intends to offer shares of its common stock and warrants to purchase its common stock in an underwritten public offering. The shares of common stock and warrants to purchase common stock are being offered as units. The shares of common stock and warrants are immediately separable and will be issued separately. Raymond James will act as sole book-running manager for the offering.
The company intends to use the net proceeds from this offering to fund our operations, including the ongoing commercialization of Abstral(R) (fentanyl) Sublingual Tablets and Zuplenz(R) (ondansetron) Oral Soluble Film, our ongoing Phase 3 PRESENT study and other clinical trials of our product candidates, and for other working capital and general corporate purposes.
The securities described above are being offered by the company pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement related to the offering has been filed with the SEC. Electronic copies of the preliminary prospectus supplement may be obtained from Raymond James, Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or by accessing the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax(TM) (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral(R) (fentanyl) Sublingual Tablets and Zuplenz(R) (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements also are subject to risks, uncertainties and assumptions relating to the commercialization and development of the company's products and product candidates, including those detailed from time to time in the company's filings with the SEC, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date. The company's actual results may differ materially from those contemplated by these forward-looking statements. The company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.
Abstral is a trademark of Galena Biopharma, Inc. All other trademarks are the property of their respective owners.
CONTACT: Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
http://media.globenewswire.com/cache/16400/small/11504.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMjQ1OTgjMTY0MDA=
Coooool, was bustin yer chops Bud, lol......good luck today parDner!!!!! $$$$$
LOL...not a lot of good ones to post plus my attention is occupied elsewhere at the moment
WTH???? What happened here?????
Some kind of alternative (health) to McDonald's
Burgers? What's that all about?
$SHAK - $47.98 +26.98 (+128.48%)WOW!! Opened @ $47!!!
$SHAK - Been waiting for this one
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110171973
nice BOX, 2morrow= SHAK
GOOOOOOOO Cramer!
$RDUS - Radius Health, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
11:01 AM ET 1/28/15 | GlobeNewswire
Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced the closing of its previously announced public offering of 4,600,000 shares of common stock at a public offering price of $36.75 per share, including 600,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares of common stock.
Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering. Cowen and Company, LLC is acting as lead manager.
The offering was made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or e-mail at prospectus-ny@gs.com, or BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com.
CONTACT: Investor Relations
Barbara Ryan
Clermont Partners
bryan@radiuspharm.com
203-274-2825
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMTc0MTYjMzExNDk=
$DRYS: Wholly owned subsidiary of DRYS files for IPO:
http://www.nasdaq.com/markets/ipos/company/tankships-investment-holdings-inc-955524-77488
As of this post, DRYS is under Black Box control but trading in a tight range.
$RDUS - TODAY, JANUARY 23, 2015
5:22 AM ET Radius Health prices 4,000,000 shares of its common stock at $36.75 per share
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2200
|
Created
|
03/07/13
|
Type
|
Free
|
Moderator starbuxsux | |||
Assistants |
Company Name | Symbol | Market | Price | Shares | Offer Amount | Date Priced |
---|---|---|---|---|---|---|
LEHIGH GAS PARTNERS LP | LGP | New York Stock Exchange | $28.10 | 3,100,000 | $87,110,000 | 12/4/2013 |
See Also:Recently Priced Initial Public Offerings (IPOs)
$ECTE - ECHO THERAPEUTICS Echo Therapeutics Announces Pricing of Common Stock @ $9.50 per share [YOU SEE WHAT HAPPENED...NO NEED TO EXPLAIN LOL] PHILADELPHIA, Dec. 20, 2012 /PRNewswire/ 7:22pm Echo Therapeutics Announces Closing of Public Offering of Common Stock [Not long after.....KABOOOOOOOM!!!!!!!!] PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ 3:15pm |
---|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |